FDA Advisory Committee Rules Against AR19 for ADHD
The US Food and Drug Administration’s (FDA) Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee is not recommending approval for AR19, an investigational immediate-release, amphetamine sulfate capsule for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Other Articles in this Edition
Identifying Diagnostic Bias to Improve Outcomes of Women With ADHD
Fewer ADHD Symptoms Seen in Girls Active in Youth Sports
FDA Advisory Committee Rules Against AR19 for ADHD
High Fructose Intake May Trigger Impulsive Behavior, Aggression, and ADHD
Multiple neurodevelopmental conditions may lead to worse educational outcomes